BPC157 - 5MG
BPC-157: Effects Observed in Preclinical and Non-Human Clinical Testing
Overview BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from a gastric juice protein. Most published data come from in vitro studies and preclinical animal models (rodents, rabbits, dogs). There are few, if any, well-controlled human clinical trials published in peer-reviewed journals. The following summarizes effects reported in these non-human and preclinical studies, focusing on reproducible findings, proposed mechanisms, and limitations.
Primary reported effects
Tissue and wound healing
Accelerates healing of skin, muscle, tendon, ligament, and bone in multiple animal models.
Enhances angiogenesis (formation of new blood vessels) at injury sites, which supports tissue repair.
Promotes collagen deposition and organization, improving tensile strength of repaired tissues.
Facilitates re-epithelialization and reduced scar formation in some models.
Gastrointestinal protection and repair
Protects gastric and intestinal mucosa from ulcers, NSAID-induced damage, and experimentally induced colitis.
Reduces gastric lesion size and promotes mucosal regeneration.
Modulates gastric acid secretion in some models and stabilizes gut barrier integrity.
Anti-inflammatory effects
Reduces markers of inflammation (cytokines, edema) in injured tissues and inflammatory disease models.
Appears to shift local responses toward resolution of inflammation rather than broad systemic immunosuppression.
Angiogenesis and vascular effects
Stimulates angiogenesis via increased expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors in injured areas.
Promotes endothelial cell survival and migration in vitro.
May influence nitric oxide (NO) signaling pathways, contributing to vascular protective effects.
Neuroprotective and nervous system effects
Demonstrates neuroprotective effects in models of traumatic brain injury, spinal cord injury, peripheral nerve crush, and neurotoxicity.
Enhances nerve regeneration, functional recovery, and remyelination in several peripheral nerve and central nervous system models.
Reduces neuronal apoptosis and oxidative stress markers in experimental paradigms.
Bone and cartilage effects
Improves bone healing and callus formation in fracture models.
Shows chondroprotective effects in some models of joint injury and osteoarthritis, with reduced cartilage degradation.
Tendon and ligament repair
Accelerates tendon and ligament recovery, increases collagen organization, and improves biomechanical properties in animal tendon injury models.
Organ protection (liver, kidney, heart)
Demonstrates protective effects against experimentally induced liver injury, reducing necrosis and improving biochemical markers.
Shows nephroprotective effects in some models of acute kidney injury.
Reduces infarct size and improves cardiac function in some myocardial ischemia models.
Metabolic and muscle effects
Some studies report improved muscle healing and reduced atrophy in disuse or injury models.
Limited evidence for systemic anabolic effects; most benefits are localized to injury sites.
Proposed mechanisms of action
Modulation of growth factor signaling (including VEGF and fibroblast growth factor pathways).
Interaction with the nitric oxide (NO) system, potentially balancing NO production to protect tissues and support angiogenesis.
Promotion of cell migration, proliferation, and survival via cytoprotective signaling pathways.
Stabilization of the extracellular matrix and promotion of organized collagen deposition.
Anti-apoptotic and antioxidant effects in damaged tissues.
Dosing, administration routes, and pharmacokinetics (from preclinical studies)
Administered systemically (intraperitoneal, subcutaneous, intravenous) or locally (intramuscular, topical, intra-articular) in animal studies.
Effective doses in rodents vary widely across studies; translation to human-equivalent dosing is not established.
Short peptide with presumed
BPC-157: Effects Observed in Preclinical and Non-Human Clinical Testing
Overview BPC-157 (Body Protection Compound-157) is a pentadecapeptide derived from a gastric juice protein. Most published data come from in vitro studies and preclinical animal models (rodents, rabbits, dogs). There are few, if any, well-controlled human clinical trials published in peer-reviewed journals. The following summarizes effects reported in these non-human and preclinical studies, focusing on reproducible findings, proposed mechanisms, and limitations.
Primary reported effects
Tissue and wound healing
Accelerates healing of skin, muscle, tendon, ligament, and bone in multiple animal models.
Enhances angiogenesis (formation of new blood vessels) at injury sites, which supports tissue repair.
Promotes collagen deposition and organization, improving tensile strength of repaired tissues.
Facilitates re-epithelialization and reduced scar formation in some models.
Gastrointestinal protection and repair
Protects gastric and intestinal mucosa from ulcers, NSAID-induced damage, and experimentally induced colitis.
Reduces gastric lesion size and promotes mucosal regeneration.
Modulates gastric acid secretion in some models and stabilizes gut barrier integrity.
Anti-inflammatory effects
Reduces markers of inflammation (cytokines, edema) in injured tissues and inflammatory disease models.
Appears to shift local responses toward resolution of inflammation rather than broad systemic immunosuppression.
Angiogenesis and vascular effects
Stimulates angiogenesis via increased expression of vascular endothelial growth factor (VEGF) and other pro-angiogenic factors in injured areas.
Promotes endothelial cell survival and migration in vitro.
May influence nitric oxide (NO) signaling pathways, contributing to vascular protective effects.
Neuroprotective and nervous system effects
Demonstrates neuroprotective effects in models of traumatic brain injury, spinal cord injury, peripheral nerve crush, and neurotoxicity.
Enhances nerve regeneration, functional recovery, and remyelination in several peripheral nerve and central nervous system models.
Reduces neuronal apoptosis and oxidative stress markers in experimental paradigms.
Bone and cartilage effects
Improves bone healing and callus formation in fracture models.
Shows chondroprotective effects in some models of joint injury and osteoarthritis, with reduced cartilage degradation.
Tendon and ligament repair
Accelerates tendon and ligament recovery, increases collagen organization, and improves biomechanical properties in animal tendon injury models.
Organ protection (liver, kidney, heart)
Demonstrates protective effects against experimentally induced liver injury, reducing necrosis and improving biochemical markers.
Shows nephroprotective effects in some models of acute kidney injury.
Reduces infarct size and improves cardiac function in some myocardial ischemia models.
Metabolic and muscle effects
Some studies report improved muscle healing and reduced atrophy in disuse or injury models.
Limited evidence for systemic anabolic effects; most benefits are localized to injury sites.
Proposed mechanisms of action
Modulation of growth factor signaling (including VEGF and fibroblast growth factor pathways).
Interaction with the nitric oxide (NO) system, potentially balancing NO production to protect tissues and support angiogenesis.
Promotion of cell migration, proliferation, and survival via cytoprotective signaling pathways.
Stabilization of the extracellular matrix and promotion of organized collagen deposition.
Anti-apoptotic and antioxidant effects in damaged tissues.
Dosing, administration routes, and pharmacokinetics (from preclinical studies)
Administered systemically (intraperitoneal, subcutaneous, intravenous) or locally (intramuscular, topical, intra-articular) in animal studies.
Effective doses in rodents vary widely across studies; translation to human-equivalent dosing is not established.
Short peptide with presumed